Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Neonc Technologies, Inc.
Ariceum Therapeutics GmbH
ImmunityBio, Inc.
Transgene
TuHURA Biosciences, Inc.
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC
Vincerx Pharma, Inc.
Fate Therapeutics
Exicure, Inc.
Incyte Corporation
MultiVir, Inc.